Repeatability of [18F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patientsGuilherme Domingues Kolinger, Ronald Boellaard, Otto S. Hoekstra et al.|EJNMMI Research|2019Cited by 49
1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinibHelena A. Yu, Xiuning Le, Jonathan W. Goldman et al.|Annals of Oncology|2021Cited by 47
Abstract LB078: Tumor genomics in patients (pts) with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib therapy in the Phase II ORCHARD studyRyan J. Hartmaier, Zofia Piotrowska, Aleksandra Markovets et al.|Cancer Research|2022Cited by 12